API companies are accelerating production expansion, and the pharmaceutical industry in the industry chain is expected to benefit

Recently, Xingputai Biopharmaceutical Co.
, Ltd.
, with a total investment of 1.
03 billion yuan, kicked off its construction in Taixing Economic Development Zone
.
It is understood that the Xingputai peptide API project was invested and constructed by Shanghai Shengpuzetai Pharmaceutical Technology Co.
, Ltd.
, with a total investment of 1.
03 billion yuan, covering an area of ​​120 acres, and constructing an annual output of 1100 kilograms of high value-added peptide APIs, covering diabetes Polypeptide therapy fields such as therapy, anticoagulation, and varicose vein therapy
.
The project is expected to realize the industrialization of high-quality peptide APIs and guide the pharmaceutical industry chain of Taixing Economic Development Zone to climb to the high end of the value chain
.
A large number of API companies are accelerating the expansion of production (picture source: Pharmaceutical Network) It is worth noting that in October, Hubei Hendy Pharmaceutical Co.
, Ltd.
announced that it plans to land on the Shenzhen Stock Exchange’s Growth Enterprise Market and issue no more than 60 million shares.
, Also stated that it plans to raise 1.
19 billion yuan for the project with an annual output of 5,000 tons of ibuprofen, a project with an annual output of 1,200 tons, an anti-tumor drug project with an annual output of 12 tons, and a supplementary working capital project
.
The industry believes that the above companies have chosen to raise funds to expand production projects.
In fact, they are mainly optimistic about the development prospects of APIs.
At present, many API companies in China have smelled the direction of industrial upgrading and are planning to seize the market in this field through various layouts.
High ground
.
For example, in terms of production expansion, since 2020, companies including Aoxiang Pharmaceutical, Fuxiang, Tianyu, Anglikang, Xianju Pharmaceutical and other companies have all announced fixed increase plans.
Fundraising is used to expand production, and Fund-raising products are mostly products that are in the lead-in period or the fast-volume period
.
Among them, from the factors that drive companies to set up new or expanded API projects, there are also many reasons, including the bottom-up demand transmission of centralized procurement policies, safety and environmental protection supervision, temporary expansion behavior
.
In this regard, the industry believes that under the background of enterprises expanding production, it just reflects the high prosperity of China's API industry
.
It is worth noting that, in the context of the continuous improvement of the API industry, the industry expects it will also bring about an improvement in the prosperity of pharmaceutical equipment
.
Among them, especially low-cost and high-efficiency pharmaceutical equipment, or will lead to new trends in the production of raw materials
.
It is understood that in different production links of APIs, a large number of production equipment with different missions are required
.
Such as equipment used for synthesis reaction, fermentation, extraction, crystallization, metering and material storage, such as reaction tanks, fermentation tanks, extraction equipment, etc.
; equipment used for solid-liquid separation, such as filtration equipment such as sterilization filters, filter presses, etc.

.
Therefore, under the background that a large number of raw material pharmaceutical companies have established sites and upgraded and expanded their production, pharmaceutical equipment companies will also usher in more demand, and their market will continue to expand accordingly
.
However, it should be noted that, as the country’s supervision of the API industry has become more stringent in recent years, and the focus on pollution problems, the author believes that the relevant pharmaceutical equipment industry also needs to be continuously upgraded in the direction of intelligence.
It is necessary to better balance economic and social benefits when designing
.
In order to respond to market competition and meet user needs, it is reported that many domestic pharmaceutical equipment companies have actually begun to take action
.
On November 19th, Chutian Technology released two innovative overall solutions for aseptic products, one of which is an overall solution for aseptic freeze-dried API isolator to deal with the problem of APIs
.
According to reports, the overall solution is developed for the aseptic freeze-dried API market, which can realize the continuity of freeze-drying, discharging, crushing, mixing and sub-packaging processes.
The entire process is isolated, sealed, and automated, and can help API users to meet the green Low-carbon requirements ensure the quality of pharmaceutical production
.
At the same time, due to the use of isolator technology to replace traditional open manufacturing, it is also conducive to reducing the user's operation and maintenance costs, and reducing the impact of dust diffusion on the environment and personnel
.
In addition to Chutian Technology, many pharmaceutical machinery companies are also innovating and upgrading API pharmaceutical equipment
.
For example, a pharmaceutical machinery company will integrate new technologies into the R&D and production of API equipment, and develop a liquid nitrogen freeze dryer that uses liquid nitrogen as a cold source to cool the system, reducing energy consumption, water consumption, manpower requirements and Wastewater treatment costs and a fully automatic solid-liquid separation solution that improves product recovery
.